'Low-Hanging Fruit' Of Industry Comms Policy Addressed By Recent FDA Documents
Executive Summary
Draft guidance documents issues by US FDA in January did not tackle the toughest off-label speech debates, but they did provide some useful information to guide company communications, experts said on a recent FDLI webinar.
You may also be interested in...
FDA Cracks Open Door For More Manufacturer Communications
Two draft guidance documents would allow a broader range of communications with payers and others about information not included on device labeling, or concerning products without FDA approval.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.